Lig­and Phar­ma part­ner wins Chi­nese ap­proval for an­ti-PD-1; Brick­ell re­ceives ex­clu­sive rights to DYRK1A in­hibitor

Cal­i­for­nia bio­phar­ma com­pa­ny Lig­and Phar­ma­ceu­ti­cals an­nounced to­day that part­ner Glo­ria Bio­sciences has re­ceived a new ap­proval from Chi­na’s Na­tion­al Med­ical Prod­ucts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER